Alzheimer's Disease Clinical Trial
Official title:
Can Early Counseling and Support for Alzheimer's Disease Caregivers Improve Burden? A Multi-centre Active Randomized Clinical Trial in Local Health Services
This randomized trial evaluates the efficacy of counselling for reducing anxiety and depression in caregivers of patients with dementia. Half of the participants will receive six hours providing counselling and psycho-social support to caregivers along with a specific telephone support service - Ad Hoc Telephone Counselling whereas the remaining participants will receive six hours providing general information about Alzheimer Disease.
This study will be a multicentre Umbrian PROBE design (treatment regimens are blinded to
both caregivers and evaluators) with investigating the effectiveness comparing two active
treatment "counseling and support" versus "educational group focusing on AD" in 230 primary
caregivers of AD patients.
If all inclusion criteria are met, the caregiver will be asked to sign a written informed
consent form. Failure to do so, will result in exclusion from the study. The treatment will
not be disclosed to the caregivers, although the caregivers will be told that they will
participate in a study with two different active treatments which will require a total of
six-hour sessions.
Care providers and Study settings
Caregiver will be recruited in secondary outpatient clinic located in Umbrian health
maintenance organizations (HMO). Outpatient clinic in Umbria are disseminated in the
territory and each small city has its own clinic (Città di Castello, Foligno, Gualdo Tadino,
Gubbio, Perugia, Marsciano, Passignano, San Giustino, Spoleto, Terni, Todi, Umbertide with
population ranging from 11,000 to 166,000 inhabitants, of them around 70% living in the
country/small village). Care providers were neurologist and geriatrician with twelve to 30
year experience in dementia practice, working in high volume outpatient clinic.
INTERVENTION
Treatment arm
Psychosocial Intervention
Every caregiver will be assigned to a permanent counselor. The caregiver in the intervention
arm will meet the counselors six times in person. The first and the last sessions will be
attended by the caregiver only whereas the remaining four sessions will be attended by the
caregiver and other family members who are involved in the daily management of the patient.
All meetings will held within 4 months of the initial assessment. Interventions will be
tailored for the caregivers based upon:
1. depression and anxiety;
2. burden;
3. self care and health-related behavior;
4. social support; and
5. behavioral symptoms.
The design and management of the structured intervention will follow a published counseling
caregiver manual, based on the experiences matured at New York University. Every session
will be documented.
Moreover, the counselor will make three ad hoc telephone calls to the caregiver each month
following the six in-person sessions counseling, in order to monitor the well-being of the
caregiver. Telephone communications will be documented; other types of communication will
not be considered valid (e.g. telephone text messages or social network messages).
Finally, the counselor will be available to the caregiver via a telephone service.
All counselors will meet monthly to update the the adherence to the protocol to resolve any
problems.
Educational Intervention on AD
The caregiver enrolled in this arm:
1. will not receive counseling or support;
2. will participate to group sessions;
3. the six hours sessions will divulge information on AD using a slide-show.
Each session will focus on the following topic:
1. diagnosis and treatment,
2. cognitive deficit management,
3. behavioral disturbance management,
4. daily living management,
5. non-pharmacological treatment,
6. legal issues and available health and social services.
Additionally, contrary to other arm, caregivers will not receive any telephone calls after
the end of the educational sessions.
Whenever a caregiver in this arm requires additional support, he/she will be referred to
volunteers of the local Alzheimer's Association.
Follow-up evaluation
Caregivers will be evaluated at 6, 12, and 24 months after baseline evaluation; outcome
measures will repeated at every evaluation. Patients will be evaluated every twelve months
after baseline, as standard care requires. The implementation of the intervention program
will be closely monitored, including activities as well as outcomes. The activities and
progress of each caregiver and family will be tracked. The participation and attrition rate
will be calculated and reported; the causes of delays in scheduling or attrition due to a
move to another city or state, hospitalization, a nursing home admission, or death will be
recorded.
The study will be under constant monitoring of an External Committee.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02089555 -
African American Alzheimer's Progression Markers - CSF and Neuro-Imaging
|
N/A |